WO1997010330A1 - Combined ligand and receptor display - Google Patents
Combined ligand and receptor display Download PDFInfo
- Publication number
- WO1997010330A1 WO1997010330A1 PCT/GB1996/002271 GB9602271W WO9710330A1 WO 1997010330 A1 WO1997010330 A1 WO 1997010330A1 GB 9602271 W GB9602271 W GB 9602271W WO 9710330 A1 WO9710330 A1 WO 9710330A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ligand
- receptor
- encoding
- nucleic acid
- molecule
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
- C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
- C12N2710/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Definitions
- the present invention relates to methods for selecting specific ligand and receptor encoding sequences and to kits for carrying out the methods.
- phages e.g. a bacteriophage such as fd (McCafferty et al, 1990, Nature, 348, 552-554) or M13
- the present invention provides an efficient screening technique to obtain corresponding ligand/receptor molecules and establishes a physical and logical connection between the two and their encoding sequences.
- This has the advantage that it is simple and rapid and opens up possibilities of applications, such as detecting new ligands and/or receptors, where both are unknown, as well as improvements regarding epitope mapping, localization of gene products and drug design.
- the present invention provides a method for selecting nucleic acid sequences encoding ligand and receptor molecules capable of specific binding to each other, the method comprising:
- step (a) expressing in a host microorganism nucleic acid encoding a surface molecule which is operably linked to the expression of nucleic acid encoding a ligand or receptor molecule, or a functional fragments thereof, so that the microorganism expresses the surface molecule and the ligand or receptor molecule as a fusion and displays it on its surface, wherein the host microorganism is modified so that it does not display the surface molecule other than as a fusion with the ligand or receptor molecule; (b) contacting the modified host microorganism of step (a) with one or more replicable genetic units capable of expressing nucleic acid encoding ligand or receptor molecules, or functional fragments thereof, the ligand or receptor molecules being candidates for specific binding to the molecules displayed by the host microorganisms of step
- the invention provides a method for selecting nucleic acid sequences encoding ligand and receptor molecules, the selection arising from modification to the host microorganism so that infection or transfer of the nucleic acid from the replicable genetic unit takes place when binding of the receptor and ligand molecules occurs.
- infection via the normal route e.g. for E. coli via wild type pili
- the host microorganism expresses and displays modified ligand molecules, with the replicable genetic units expressing the candidate receptor molecules.
- this provides a method for selecting specific ligand and receptor encoding sequences wherein:
- step (b) infecting, or in other ways transferring DNA to, the modified host organism of step (a) with a genetically modified replicable genetic unit capable of expressing a receptor, or a functional fragment thereof, fused to a surface protein of the replicable genetic unit;
- the method of the invention optionally includes the additional step of:
- the isolation can be achieved by associating different selection markers (e.g. different antibiotic resistance markers) with the nucleic acid sequences encoding the ligand and receptor molecules.
- different selection markers e.g. different antibiotic resistance markers
- the host microorganisms containing nucleic acid sequences encoding a specific binding pair can be selected by growing them in the presence of both antibiotics.
- the vectors containing nucleic acid encoding the ligand and the receptor can be separated from each other by omitting one of the antibiotics from the growing medium.
- this method can be used to screen:
- the host microorganisms do not express the normal (wild type) surface molecules that are used to display ligand or receptor molecules as fusions on its surface. This means that the replicable genetic units used to display candidate binding partners of the ligand or receptor molecule will only infect the microorganisms when binding between the ligand or receptor and a binding partner takes place, i.e. infection via the normal surface molecule of the microorganism is not possible as they are not displayed.
- the host microorganism is an E. coli strain in which the F episome is mutated in the traA gene that builds up pilin molecules, but which contains the other genes required for infection by bacteriophages, e.g. traL, traE, traY etc. Accordingly, these strains of E. coli are F " , that is they do not produce functional pili, except when transformed with vectors comprising nucleic acid encoding fusions of the pilin and the ligand or receptor molecules.
- the present invention does not rely on engineering the replicable genetic units to limit their infectivity, and so obtain selectivity of DNA transfer, helping to avoid the difficulties that can be encountered in generating large libraries with deleted bacteriophages, such as pill deleted Ml3 phage.
- the vectors comprising the nucleic acid encoding the ligand and receptor molecules have different origins of replication (pMBl, pl5A, PSClOl) so that both vectors can be stably maintained when transferred to the host microorganism.
- steps (a) and (b) can be simultaneous or sequential.
- the host microorganism will be cultured so that they display the ligand or receptor molecules, prior to infection with the replicable genetic units.
- the present invention provides a method for selection of nucleic acid sequences encoding ligand and receptor molecules capable of specific binding to each other.
- the designed system enables the passage of DNA over cell membranes and is denoted “Cellular Linkage of ligand- receptor Affinity Pairs" (CLAP) .
- CLAP Cellular Linkage of ligand- receptor Affinity Pairs
- the DNA which is translocated from the replicable genetic unit over the cell membrane is denoted “membrane passage DNA” (mp-DNA) and this genetic information outside the cell can be defined, constructed, designed and developed using recombinant DNA technology.
- the type of specific DNA, which is translocated over the cell membrane, is determined by the genetic information, DNA, inside the cell.
- This genetic information inside the cell can be defined, constructed, designed and developed using recombinant DNA technology and is denoted “translocation determining DNA” (td-DNA) .
- td-DNA translocation determining DNA
- this selectivity of DNA transfer is achieved using a strain of E. coli that have a mutation in the F episome so that they do not display functional pili. This means that when they are transformed with a vector comprising nucleic acid encoding a ligand or receptor for expression as a fusion with the pili, only these modified pili are displayed on the E. coli surface.
- the CLAP system can be used to construct a genetic library of td-DNA to determine the translocation of specific mp-DNA from a genetic library of mp-DNA.
- a genetic library of td-DNA to determine the translocation of specific mp-DNA from a genetic library of mp-DNA.
- the individual td-DNA in individual cells will determine the translocation of individual mp-DNA into each cell.
- the corresponding pairs of td-DNA and mp-DNA will be linked in the same cell.
- the td-DNA can be constituted of genes encoding proteins or peptides of various sizes. Individual cells encode specific proteins/peptides defined by the td-DNA in the cell and this protein or peptide is exposed on the cell surface. These exposed proteins/peptides can be constructed as mp-DNA and displayed on the surface of a replicable genetic unit .
- proteins/peptides can be viewed as receptors and can then interact with ligand molecules exposed, encoded by the td-DNA, on the cell surface. When such interactions occur the ligand-receptor interaction mediates the passage of receptor DNA (mp-DNA) into the cell.
- the molecules on the cell surface are receptors and the molecules on the replicable genetic unit are ligands.
- a td-DNA can consist of a cDNA-library and the mp-DNA can consist of an antibody fragment gene library, where antibody fragment specificities can be selected against different protein/peptides ligand.
- the td-DNA can also consist of DNA encoding one type of peptide which can bind biotin and biotinylated chemical compounds. The biotin-peptide interaction allows the immobilization of biotinylated chemical compounds on the cell surface and these immobilized compounds can function a ⁇ ligands/receptors for determining the translocation of mp- DNA encoding receptors/ligands .
- Antibody fragments with affinity to the immobilized chemical compound can be selected from a genetic library encoding different antibody specificities/affinities.
- the mp-DNA encoding the specificity/affinity of the selected antibody fragment is then replicated inside the cell, which displayed the biotin binding peptide binding to the biotinylated chemical compound.
- Other types of modifications of the chemical compounds can be used, which bind the biotin binding peptide and other types of peptides can be displayed on the cell surface which bind the modified chemical compound.
- the present invention provides a kit containing vectors for use in the methods described herein.
- a preferred kit comprises: (a) a host microorganism modified so that it does not display a wild type surface protein;
- a bacteriophage having a site for insertion of nucleic acid encoding candidate binding partners to the ligand or receptor so that the binding partners are expressed displayed on the surface of the bacteriophage as a fusion with a surface protein of the bacteriophage.
- cDNA librarie ⁇ derived from, e.g. genome sequences, human or other tissue can be cloned into the fusion vector and subsequently transfected into the microorganism host.
- cDNA derived molecules as fusion proteins to pilin
- bacteriophages displaying antibody fragments derived from immunised or naive B cells from human or other origin will be formed and allowed to interact with the host microorganism expressing cDNA derived molecules.
- the infection event takes place and is mediated only by specific receptor-ligand interactions found between microorganisms and bacteriophages.
- the genetic information for each ligand and receptor pair can then be isolated.
- cDNA libraries derived from cancer patients and differentially PCR selected against normal tissue can be bacterially displayed, as described above.
- antibody libraries displayed on bacteriophages, derived from normal patients or cancer patients are allowed to interact with the cDNA displaying microorganisms and infection is again mediated by specific receptor-ligand interactions .
- cDNA derived from allergen encoding gene sequences can be bacterially displayed as described above.
- antibody libraries displayed on bacteriophages derived from normal or atopic patients are allowed to interact with the cDNA displaying microorganisms and infection is again mediated by specific receptor-ligand interactions .
- Figure 1 shows a schematic illustration of the CLAP infection.
- Figure 2 shows the infectivity by VCS M13 helper phages of E. coli carrying the plasmids (a) JFLO, (b) pTRAP and JCFLtraAl and (c) pTRAPCMV and JCFLtraAl .
- Figure 3 shows the infectivity of E. coli carrying the plasmids pTRAPCMV and JCFtraAl by a specific phage stock (anti-CMV) and two non-specific phage stocks (anti-lys and anti-ox) .
- library means a number of fragments of a ligand or receptor population, either their encoding sequences or their corresponding protein or peptide sequence displayed on a surface. Typically, libraries will comprise a substantial number of such nucleic acid sequences or peptides. By way of example, libraries can be constructed after the principles outlined by Huse et al, 1989, Science, 246, 1275.
- ligand and receptor refer to pairs of molecules or functional parts thereof, capable of specific binding to each other. Examples of such specific ligand- receptor pairs are: antibody-antigen, hormone-hormone receptor, growth factor-growth factor receptor, enzyme- substrate and biotin-avidin etc.
- “Host microorganisms” include bacteria such as E. coli or other Gram negative bacteria, Gram positive bacteria, as well as unicellular microorganisms of eukaryotic origin such as yeast.
- Replicable genetic unit comprises viruses and bacteriophages such as M13 , fl and fd, but also bacteria, as well as unicellular microorganisms of eukaryote origin such as yeast.
- mp-DNA membrane passage DNA
- td-DNA Translocating determining DNA
- the "surface molecule” will be dependent on the choice of host microorganism and replicable genetic unit. If the host organism is E. coli, suitable surface molecules can be selected from the group OmpA, lipoprotein, Lpp, IgA protease, LamB, fimbriae, flagellae or pilin. Pilin is preferred.
- the surface molecule can be any surface molecule involved in the infection of, or in the transformation of DNA to, the host.
- Preferred replicable genetic units are filamentous bacteriophages such as fd and
- suitable surface molecules of these phages can be protein III or protein VIII. Most preferred is protein III of the filamentous bacteriophage M13.
- selection of host organisms which have been infected, or otherwise transformed with DNA, is dependent on the fact that only host organism and replicable genetic unit pairs which have formed a receptor-ligand pair will infect each other.
- Host organisms which have been infected, or in other ways transformed with DNA can be "isolated” by the use of different selections markers such as different antibiotic resistance, e.g. ampicillin, tetracyclin or chloramphenicol, on different types of DNA.
- different selections markers such as different antibiotic resistance, e.g. ampicillin, tetracyclin or chloramphenicol, on different types of DNA.
- Encoding sequence can mean the corresponding DNA sequence of a protein or RNA or complementary DNA or RNA sequence thereof .
- protein means any sequence of amino acids including any peptide fragments thereof.
- a vector (pTRAPchl) carrying the information for the pili molecule, pilin, of E. coli was constructed.
- the traA gene, encoding the pilin was amplified by PCR from the plasmid pBF203 using:
- the amplified fragment was cut with restriction enzymes Hind III/Pst I, purified and inserted into the Hind III/Pst I site of the plasmid pAM18chl R .
- the new vector was called pTRAPchl R and formed functional pili when co-transformed with an F episome called JCFLtraAl, which has a point mutation in the traA gene (see Achtman et al, J. Bacteriol., 106 , 529-538, (1971) ) .
- the mutated episome contains all of the genes other than traA needed for the infection procedure, the traA being responsible for building up the pilin molecules.
- pAM18chl R vector was constructed by isolating the Hae II lacZ ⁇ peptide fragment from pUC18, treating with Sl nuclease and ligating into the "filled-in" Hind III/BamH I site of pACYC 184.
- a vector (pTRAPV3chl R ) was constructed that included nucleic acid encoding the pilin molecule, with an addition of nucleic acid sequence encoding a part of the V3 loop of HIV-l (V3 is the variable loop of gpl20 of HIV-l (LAI)) .
- the nucleic acid encoding the V3 loop was arranged so that it would be expressed at the C-terminal end of the pilin molecule.
- a vector (pTRAPCMVchl R ) was constructed that carries nucleic acid encoding a pilin molecule with the addition of the sequence of a part of the gB protein of CMV
- the nucleic acid encoding the gB fragment was arranged so that it would be expressed at the C-terminal end of the pilin molecule. This was achieved through PCR amplification of the traA gene from the plasmid pBF203 with a 5' primer as described above, with the following 3' primer: 5' -TCA CGG AAG CTT TCA TCA TCC GTA CTT GAG GGT AGT GTT GTA GAT AGT CTC GTT GGC GAG GCC AAC GAC GGC CAT AC, which includes 39 bases coding for 13 amino acids of the gB protein. This amplified fragment was inserted in pAM18chl R as described above. This vector was called pTRAPCMVchl R .
- a vector (pTRAPtet R ) carrying the information for the pili molecule, pilin, of E. coli was contructed.
- the traA gene, encoding the pilin was amplified by PCR from the vector pTRAPchl R (example 1) using:
- the amplified fragment was cut with restriction enzyme Ncol, purified and inserted into the Ncol site of the plasmid pACYC184 ⁇ HindIII .
- the new vector was called pTRAPtet R and was capable of forming functional pili if co- transformed with an F episome called pOX38A::CAT, which has a CAT cassette inserted into its traA gene to abolish its function.
- pACYC184 ⁇ HindIII was constructed by cutting the plasmid pACYC184 with Hindlll, treatment with Klenow and religation, to abolish the unique Hindlll site.
- a vector (pTRAPV3tet R ) was constructed that carries the information for the pilin molecule with an addition of the sequence of a part of the V3 loop of HIV-l (V3 is the variable loop of gpl20 of HIV-l (LAI) ) constructed to be expressed in the C-terminal end of the pilin molecule. This was achieved through PCR amplification of the traA gene and the V3 peptide-coding sequence from the vector pTRAPV3chl R , with the primers described in example 2a. This amplified fragment was inserted, as described above, in pACYC184 ⁇ HindIII . This vector is called pTRAPV3tet R .
- a vector (pTRAPCMVtet R ) was constructed that carries the information for the pilin molecule with an addition of the sequence of a part of the gB protein of CMV (cytomegalovirus) , constructed to be expressed in the C- terminal end of the pilin molecule. This was achieved through PCR amplification of the traA gene and the CMV peptide-coding sequence from the vector pTRAPCMVchl R , with the primers described in example 2a. This amplified fragment was inserted, as described above, in pACYC184 ⁇ HindIII . This vector was called pTRAPCMVtet R .
- a vector (pAM18tet R ) was constructed by PCR amplification of the pUC-insert from pAM18chl R , containing a lacZ a peptide fragment, using primers as described in example 2a. This amplified fragment was inserted, as described above, in pACYC184 ⁇ HindIII . This vector was called pAM18tet R .
- E. coli strain TGI was used for the genetic constructions.
- the filamentous bacteriophage VCS M13 (helper phage) was obtained from Stratagene.
- the phages obtained carry the antibody Fab fragments linked by the heavy chain constant domain to the N-terminal of protein III (pill) or the antibody scFv fragments linked by the light chain variable domain to the N-terminal of pill.
- E. coli cells were established; (a) E. coli strain JC 3272, containing the unmutated F episome (JCFLO) (b) E. coli strain ED 2601, containing the F episome mutated in the traA gene (JCFLtraAl) and transformed with the pTRAP vector and (c) E. coli strain ED 2601, containing the F episome mutated in the traA gene (JCFLtraAl) and transformed with the pTRAPCMV vector.
- JCFLO unmutated F episome
- Infections assays were carried out by incubating 100 ⁇ l of E. coli with 10 ⁇ l of phage stock at room temperature for 45 minutes, followed by plating on LB agar plates with the appropriate antibiotics (kanamycin for the helper phage ⁇ and ampicillin for the specific phages, and chloramphenicol for the pTRAP constructs) . The number of colony forming units, cfu, per plate were counted after overnight incubation in 37°C.
- FIG. 2(a) shows that the wild type of VCS M13 expressing the pill on the surface infects the F episome, JCFLO, containing E. coli .
- FIG. (b) E coli containing the F episome mutated in the traA gene, JCFLtraAl, and co-transformed with the pTRAP vector is infected by the VCS M13.
- This construct thus led to the formation of functional F pili, whereas the co- transformation with pTRAPCMV in figure 2 (c) completely blocked with infection of wild type VCS M13 phage.
- a comparison of figure 2 (a) and (b) shows that the number of cfu obtained using the constructs of the invention (figure 2(b)) was comparable to the wt situation (figure 2(a)) .
- FIG. 3 shows the specificity of the infection.
- the anti-ox and anti-lys containing phages, expressing the anti-phenyl oxazolone or the anti- lysozyme antibody fragments connected to the pill surface did not infect the host carrying the gB of CMV on the pili due to lack of specificity.
- the antigen specific infection mediated by 13 amino acid peptide of gB on the pilin molecule, was clearly demonstrated by anti-CMV phages, which gave > 700 cfu/plate.
- the two plasmids encoding gB peptide (ligand) and anti-CMV scFv (receptor) were physically linked by the boundaries of the cell membrane.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Computational Biology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Luminescent Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU69391/96A AU698653B2 (en) | 1995-09-13 | 1996-09-13 | Combined ligand and receptor display |
JP9511771A JPH11512288A (en) | 1995-09-13 | 1996-09-13 | Bound ligand and receptor display |
EP96930279A EP0850299B1 (en) | 1995-09-13 | 1996-09-13 | Combined ligand and receptor display |
AT96930279T ATE290075T1 (en) | 1995-09-13 | 1996-09-13 | COMBINED LIGAND AND RECEPTOR UNFOLDING |
US09/043,230 US6607881B1 (en) | 1995-09-13 | 1996-09-13 | Combined ligand and receptor display |
DE69634409T DE69634409T2 (en) | 1995-09-13 | 1996-09-13 | COMBINED LIGAND AND RECEPTOR DEVELOPMENT |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE9503151-4 | 1995-09-13 | ||
SE9503151A SE9503151D0 (en) | 1995-09-13 | 1995-09-13 | Combined ligand and receptor display |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/043,230 A-371-Of-International US6607881B1 (en) | 1995-09-13 | 1996-09-13 | Combined ligand and receptor display |
US10/387,630 Continuation US20030224410A1 (en) | 1995-09-13 | 2003-03-13 | Combined ligand and receptor display |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997010330A1 true WO1997010330A1 (en) | 1997-03-20 |
Family
ID=20399452
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1996/002271 WO1997010330A1 (en) | 1995-09-13 | 1996-09-13 | Combined ligand and receptor display |
Country Status (9)
Country | Link |
---|---|
US (2) | US6607881B1 (en) |
EP (1) | EP0850299B1 (en) |
JP (1) | JPH11512288A (en) |
AT (1) | ATE290075T1 (en) |
AU (1) | AU698653B2 (en) |
CA (1) | CA2230483A1 (en) |
DE (1) | DE69634409T2 (en) |
SE (1) | SE9503151D0 (en) |
WO (1) | WO1997010330A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032017A1 (en) * | 1996-02-26 | 1997-09-04 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides |
EP0932670A1 (en) * | 1996-03-25 | 1999-08-04 | Maxygen, Inc. | Evolving cellular dna uptake by recursive sequence recombination |
EP0944737A1 (en) * | 1996-11-07 | 1999-09-29 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Representations of bimolecular interactions |
WO1999056129A1 (en) | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
WO2000014216A1 (en) * | 1998-09-04 | 2000-03-16 | Zk Pharmaceuticals, Inc. | Method for selecting peptides inhibiting viral surface protein binding to cell surface receptor |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
WO2003004643A2 (en) | 2001-07-03 | 2003-01-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Reversed mammalian protein-protein interaction trap |
EP1612221A2 (en) | 2000-05-22 | 2006-01-04 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Receptor-based interaction trap |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
WO2012117031A1 (en) | 2011-03-01 | 2012-09-07 | Vib Vzw | Kinase substrate sensor |
WO2013131957A1 (en) | 2012-03-06 | 2013-09-12 | Vib Vzw | Membrane span-kinase fusion protein and the uses thereof |
WO2013174999A1 (en) | 2012-05-24 | 2013-11-28 | Vib Vzw | Virus-like particle based protein-protein interaction |
US10379115B2 (en) | 2015-03-23 | 2019-08-13 | Universiteit Gent | Virus-like particle (VLP) based small molecule-protein interaction trap |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7056679B2 (en) * | 2001-10-24 | 2006-06-06 | Antyra, Inc. | Target specific screening and its use for identifying target binders |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0614989A1 (en) * | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
WO1995016027A1 (en) * | 1993-12-06 | 1995-06-15 | Bioinvent International Ab | Method of selecting specific bacteriophages |
WO1995034648A1 (en) * | 1994-06-10 | 1995-12-21 | Dade International Inc. | A method for displaying proteins |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023171A (en) * | 1989-08-10 | 1991-06-11 | Mayo Foundation For Medical Education And Research | Method for gene splicing by overlap extension using the polymerase chain reaction |
EP0575410B1 (en) | 1991-03-07 | 1999-05-19 | BRADBURY, Andrew Raymon Morton | Selection of specific proteins by a biological method |
EP0656941B1 (en) * | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
-
1995
- 1995-09-13 SE SE9503151A patent/SE9503151D0/en unknown
-
1996
- 1996-09-13 JP JP9511771A patent/JPH11512288A/en active Pending
- 1996-09-13 WO PCT/GB1996/002271 patent/WO1997010330A1/en active IP Right Grant
- 1996-09-13 US US09/043,230 patent/US6607881B1/en not_active Expired - Fee Related
- 1996-09-13 AU AU69391/96A patent/AU698653B2/en not_active Ceased
- 1996-09-13 AT AT96930279T patent/ATE290075T1/en not_active IP Right Cessation
- 1996-09-13 DE DE69634409T patent/DE69634409T2/en not_active Expired - Lifetime
- 1996-09-13 EP EP96930279A patent/EP0850299B1/en not_active Expired - Lifetime
- 1996-09-13 CA CA002230483A patent/CA2230483A1/en not_active Abandoned
-
2003
- 2003-03-13 US US10/387,630 patent/US20030224410A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0614989A1 (en) * | 1993-02-17 | 1994-09-14 | MorphoSys AG | A method for in vivo selection of ligand-binding proteins |
WO1995016027A1 (en) * | 1993-12-06 | 1995-06-15 | Bioinvent International Ab | Method of selecting specific bacteriophages |
WO1995034648A1 (en) * | 1994-06-10 | 1995-12-21 | Dade International Inc. | A method for displaying proteins |
Cited By (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997032017A1 (en) * | 1996-02-26 | 1997-09-04 | Morphosys Gesellschaft Für Proteinoptimierung Mbh | Novel method for the identification of nucleic acid sequences encoding two or more interacting (poly)peptides |
US6391552B2 (en) | 1996-03-25 | 2002-05-21 | Maxygen, Inc. | Enhancing transfection efficiency of vectors by recursive recombination |
EP0932670A1 (en) * | 1996-03-25 | 1999-08-04 | Maxygen, Inc. | Evolving cellular dna uptake by recursive sequence recombination |
EP0932670A4 (en) * | 1996-03-25 | 1999-08-04 | ||
US6096548A (en) * | 1996-03-25 | 2000-08-01 | Maxygen, Inc. | Method for directing evolution of a virus |
US6482647B1 (en) | 1996-03-25 | 2002-11-19 | Maxygen, Inc. | Evolving susceptibility of cellular receptors to viral infection by recursive recombination |
US6358742B1 (en) | 1996-03-25 | 2002-03-19 | Maxygen, Inc. | Evolving conjugative transfer of DNA by recursive recombination |
US6387702B1 (en) | 1996-03-25 | 2002-05-14 | Maxygen, Inc. | Enhancing cell competence by recursive sequence recombination |
EP0944737A1 (en) * | 1996-11-07 | 1999-09-29 | RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. | Representations of bimolecular interactions |
EP0944737A4 (en) * | 1996-11-07 | 2004-11-10 | Univ Ramot | Representations of bimolecular interactions |
US8974792B2 (en) | 1998-04-24 | 2015-03-10 | The Regents Of The University Of California | Internalizing erbB2 antibodies |
US8173424B2 (en) | 1998-04-24 | 2012-05-08 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
EP1073905A1 (en) * | 1998-04-24 | 2001-02-07 | The Regents of the University of California | Methods of selecting internalizing antibodies |
US9388244B2 (en) | 1998-04-24 | 2016-07-12 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
EP1073905A4 (en) * | 1998-04-24 | 2004-12-08 | Univ California | Methods of selecting internalizing antibodies |
WO1999056129A1 (en) | 1998-04-24 | 1999-11-04 | The Regents Of The University Of California | Methods of selecting internalizing antibodies |
US7244826B1 (en) | 1998-04-24 | 2007-07-17 | The Regents Of The University Of California | Internalizing ERB2 antibodies |
US7892554B2 (en) | 1998-04-24 | 2011-02-22 | The Regents Of The University Of California | Internalizing ErbB2 antibodies |
WO2000014216A1 (en) * | 1998-09-04 | 2000-03-16 | Zk Pharmaceuticals, Inc. | Method for selecting peptides inhibiting viral surface protein binding to cell surface receptor |
US6479280B1 (en) | 1999-09-24 | 2002-11-12 | Vlaams Interuniversitair Institutuut Voor Biotechnologie Vzw | Recombinant phages capable of entering host cells via specific interaction with an artificial receptor |
EP1612221A2 (en) | 2000-05-22 | 2006-01-04 | Vlaams Interuniversitair Instituut voor Biotechnologie vzw. | Receptor-based interaction trap |
US8048986B2 (en) | 2001-07-03 | 2011-11-01 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Reversed mammalian protein-protein interaction trap |
WO2003004643A2 (en) | 2001-07-03 | 2003-01-16 | Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw | Reversed mammalian protein-protein interaction trap |
WO2012117031A1 (en) | 2011-03-01 | 2012-09-07 | Vib Vzw | Kinase substrate sensor |
US10280410B2 (en) | 2011-03-01 | 2019-05-07 | Universiteit Gent | Cytoplasmic protein complex comprising a kinase substrate sensor cells and associated detection methods |
US11242511B2 (en) | 2011-03-01 | 2022-02-08 | Vib Vzw | Cytoplasmic protein complex comprising a kinase substrate sensor, cells comprising the complex, and associated detection methods |
WO2013131957A1 (en) | 2012-03-06 | 2013-09-12 | Vib Vzw | Membrane span-kinase fusion protein and the uses thereof |
US11053300B2 (en) | 2012-03-06 | 2021-07-06 | Vib Vzw | Membrane span-kinase fusion protein and the uses thereof |
US10336811B2 (en) | 2012-03-06 | 2019-07-02 | Vib Vzw | Membrane span-kinase fusion protein and the uses thereof |
WO2013174999A1 (en) | 2012-05-24 | 2013-11-28 | Vib Vzw | Virus-like particle based protein-protein interaction |
US10444245B2 (en) | 2012-05-24 | 2019-10-15 | Vib Vzw | Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins |
US11237174B2 (en) | 2012-05-24 | 2022-02-01 | Vib Vzw | Method for detecting protein-protein interactions in a cell utilizing particle-forming polypeptide-bait fusion proteins and virus-like particles |
US10641765B2 (en) | 2015-03-23 | 2020-05-05 | Vib Vzw | Virus-like particle (VLP) based small molecule-protein interaction trap |
US11231416B2 (en) | 2015-03-23 | 2022-01-25 | Vib Vzw | Virus-like particle (VLP) based small molecule-protein interaction trap |
US10379115B2 (en) | 2015-03-23 | 2019-08-13 | Universiteit Gent | Virus-like particle (VLP) based small molecule-protein interaction trap |
Also Published As
Publication number | Publication date |
---|---|
CA2230483A1 (en) | 1997-03-20 |
EP0850299B1 (en) | 2005-03-02 |
DE69634409D1 (en) | 2005-04-07 |
SE9503151D0 (en) | 1995-09-13 |
ATE290075T1 (en) | 2005-03-15 |
AU698653B2 (en) | 1998-11-05 |
US6607881B1 (en) | 2003-08-19 |
EP0850299A1 (en) | 1998-07-01 |
JPH11512288A (en) | 1999-10-26 |
AU6939196A (en) | 1997-04-01 |
US20030224410A1 (en) | 2003-12-04 |
DE69634409T2 (en) | 2006-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU698653B2 (en) | Combined ligand and receptor display | |
US20200318099A1 (en) | Polypeptide display libraries and methods of making and using thereof | |
US5766905A (en) | Cytoplasmic bacteriophage display system | |
Mikawa et al. | Surface display of proteins on bacteriophage λ heads | |
US5514548A (en) | Method for in vivo selection of ligand-binding proteins | |
JP3210342B2 (en) | Total synthetic affinity reagent | |
KR100425966B1 (en) | Substance for microstructure production and its use | |
Malmborg et al. | Selective phage infection mediated by epitope expression on F pilus | |
WO1995034683A1 (en) | Method of detecting compounds utilizing genetically modified lambdoid bacteriophage | |
EP0614989A1 (en) | A method for in vivo selection of ligand-binding proteins | |
Russel et al. | Filamentous phage | |
AU3763893A (en) | Methods for producing members of specific binding pairs | |
US6599697B1 (en) | Process for preparing a multicombinatorial library of vectors for expressing antibody genes | |
Schatz et al. | [10] Screening of peptide libraries linked to lac repressor | |
EP0575410B1 (en) | Selection of specific proteins by a biological method | |
EP0675953B1 (en) | Soluble peptides having constrained, secondary conformation in solution and method of making same | |
RU2540010C2 (en) | PHAGE DISPLAY ON pIX PROTEIN INDEPENDENT FROM SIGNAL SEQUENCE | |
US6040141A (en) | Bacteria for preparing stable fusion proteins and methods for detecting the same | |
US20100240547A1 (en) | Methods for selecting protein binding moieties | |
US20050003384A1 (en) | Surface expression libraries of heteromeric receptors | |
US20030104604A1 (en) | Genetically engineered bacterial strains for the display of foreign peptides on filamentous phage | |
AU6714194A (en) | Method of detecting compounds utilizing chemically modified lambdoid bacteriophage | |
US20050130124A1 (en) | Phagemid display system | |
US5646030A (en) | Method for isolating mutant cells | |
WO1992022657A1 (en) | Antigen-enzyme conjugate expression and detection system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2230483 Country of ref document: CA Ref country code: CA Ref document number: 2230483 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996930279 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 511771 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09043230 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1996930279 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 1996930279 Country of ref document: EP |